Comparison of gemcitabine plus cisplatin versus capecitabine plus cisplatin as first‐line chemotherapy for advanced biliary tract cancer

Aim: It remains unclear whether capecitabine combined with cisplatin would show similar effects compared with standard therapy using gemcitabine and cisplatin in advanced biliary tract cancer (BTC). Methods: Patients with advanced BTC who were treated with first‐line chemotherapy at Asan Medical Cen...

Full description

Saved in:
Bibliographic Details
Published in:Asia-Pacific journal of clinical oncology 2017-02, Vol.13 (1), p.13-20
Main Authors: Park, Kwonoh, Kim, Kyu‐pyo, Park, Seongjoon, Chang, Heung‐Moon
Format: Article
Language:English
Subjects:
Adult
Aged
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Biliary tract
biliary tract cancer
Biliary Tract Neoplasms - drug therapy
Biliary Tract Neoplasms - mortality
Cancer
capecitabine
Capecitabine - administration & dosage
Capecitabine - adverse effects
Chemotherapy
Cisplatin
Cisplatin - administration & dosage
Cisplatin - adverse effects
Deoxycytidine - administration & dosage
Deoxycytidine - adverse effects
Deoxycytidine - analogs & derivatives
Disease-Free Survival
Female
Gemcitabine
Humans
Male
Middle Aged
Multivariate analysis
Proportional Hazards Models
Retrospective Studies
Survival
Treatment Outcome
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Aim: It remains unclear whether capecitabine combined with cisplatin would show similar effects compared with standard therapy using gemcitabine and cisplatin in advanced biliary tract cancer (BTC). Methods: Patients with advanced BTC who were treated with first‐line chemotherapy at Asan Medical Center were retrospectively analyzed. All patients received either cisplatin followed by gemcitabine on days 1 and 8 every 3 weeks (GP group), or capecitabine on days 1–14 with cisplatin on day 1 every 3 weeks (XP group). Results: Of the 134 patients who met the inclusion criteria, 78 received XP and 56 were treated with GP. After a median follow‐up of 26.2 months, the progression‐free survival was 5.7 months for XP versus 4.1 months for GP (hazard ratio [HR] = 0.81, P = 0.31). The overall survival (OS) was 11.0 months for XP versus 9.8 months for GP (HR = 0.84, P = 0.36). In the multivariate analysis, there were no significant differences in PFS and OS between the two groups. Conclusion: XP seems to be as effective as GP in patients with advanced BTC. The XP regimen is feasible and might offer increased convenience regarding the schedule of drug administration.
ISSN:1743-7555
1743-7563
DOI:10.1111/ajco.12592